SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

NCT03433183 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Malignant Peripheral Nerve Sheath Tumors
Neurofibromatosis 1

Interventions

DRUG: Selumetinib
DRUG: Sirolimus

Sponsor

Sarcoma Alliance for Research through Collaboration

Collaborators

[object Object]
[object Object]